 SOUTH SAN FRANCISCO, Calif. CASTRES, France--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel tab-cel in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus EBV-positive cancers. Atara will retain full rights to tab-cel in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive 